NovaMedica is a modern Russian pharmaceutical company established in 2012 by leading U.S. venture capital firm Domain Associates LLC and RUSNANO, an investment fund that implements state policy for the development of Russia’s high-technology industries.
NovaMedica has developed a well-established infrastructure to promote and sell pharmaceutical products in the Russian market. Its portfolio currently includes 25 products in ophthalmology and gastroenterology.
NovaMedica's strategy is focused on the search, registration and localization in Russia of innovative pharmaceutical products and technologies, as well as the development of the company’s own research and development activities and the establishment of a GMP-compliant pharmaceutical production facility in Russia.
NovaMedica is currently building a Technology Center in Moscow that will include R&D laboratories and production facilities for advanced technologies previously unavailable on the Russian pharmaceutical market.
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
24 March 2017
23 March 2017